Transparency Market Research

Albany, NY -- (SBWIRE) -- 03/29/2016 -- A new market research report by Transparency Market Research, titled "Circulating Biomarkers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020," presents a detailed analysis of the market and has been collated by conducting both primary as well as secondary research. A number of market dynamics such as drivers, restraints, challenges, trends, and opportunities have been detailed along with presenting their impact on the growth of the market. The parent segments as well as the sub-segments present in the market have also been evaluated in detail within this study. The leading sub-segment as well as its predicted state by the end of the forecast horizon has also been presented under this report.

The report also presents a SWOT analysis of the prime market segments. The geographical segmentation section of the report provides a bird's eye view of the key regions dominant in the market for circulating biomarkers and the region expected to grow at the highest growth rate by the end of the forecast horizon. The competitive landscape section of the study includes the prominent players operating the market along with providing their product specifications, new product introductions, and a SWOT analysis.

As per the report, circulating biomarkers are a vital part of healthcare management owing to its utilization in disease progression monitoring, in biopsies, and for measuring the effectiveness of treatment regimens. By using circulating biomarkers, the prognosis of patients is analyzed in order to improve drug advancement. Biomarkers are also utilized for revolutionizing personalized medicine and can be applied to each stage of cancer patient care. Numerous circulating biomarkers of prognostic and diagnostic utility in heart failures are currently being studied.

In terms of geography, the report segments the market into Europe, Asia Pacific, North America, and Rest of the World (RoW). Amongst these, the region of North America led the market in 2014 and was trailed by Europe. The rising occurrence of cancer and the increasing usage of circulating biomarkers within drug discovery are amongst the major factors propelling the circulating biomarkers market in these two regions. On the other hand, Asia Pacific is amongst the most swiftly developing circulating biomarkers markets and provides lucrative opportunities for the overall growth of this market in the coming years. The rapid advancement in personalized medicines and the increasing developments in sequencing technology are amongst the chief factors propelling the circulating biomarkers market in Asia Pacific.

As stated in the report, the prime players operating in the market are Abbott Laboratories, Becton, Dickinson and Company, GE Healthcare, Epigenomics AG, Agilent Technologies, Inc., Biocept, Inc. and Affymetrix, Inc. among others.